Fitusiran · Qfitlia

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Hemophilia A and B

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
CN
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with severe hemophilia A or B (Qfitlia; NMPA)
Product first approved 2025sec.gov

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Hemophilia A and B
Other / comorbidity
Phase 2/3 (1)
Other / comorbidity
NCT03974113 · Genzyme, a Sanofi Company
2020-01-28 – 2026-08-04 · Hemophilia
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT02554773 · Genzyme, a Sanofi Company
2015-09-18 – 2023-03-21 · Hemophilia A, Hemophilia B
What this study did
Phase 4 (1)
Other / comorbidity

Competitive landscape

This drug's own stage for Hemophilia A and B: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fitusiran (Qfitlia): this drugApprovedRNA / oligonucleotideAntithrombin (SERPINC1) mRNAPartial signal
NCT03417245: Estimated mean annualised bleeding rate: 3·1 fitusiran vs 31·0 on-demand factor (rate ratio 0·101; p<0·0001)
NCT03549871: Estimated mean ABR reduced by 79.7% (P = .0021) and 46.4% (P = .0598) vs BPA/CFC prophylaxis, respectively
Zemocimig
Phase 1(overall)
Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Qfitlia (Fitusiran) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
Phase 3HemophiliaActive not recruiting
Est. primary completion 2027-03-25 · NCT05662319 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Phase 4Hemophilia ARecruiting
Est. primary completion 2028-05-28 · NCT06145373 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
Phase 3HemophiliaRecruiting
Est. primary completion 2029-08-04 · NCT07285460 · CT.gov ↗
What to watch

See the full readout calendar ↗